Navigation Links
'Watchful Waiting' Often Best Strategy for Slow-Moving Prostate Cancer
Date:6/18/2010

Surgery, radiation not always ideal for many with low risk disease, researchers find

FRIDAY, June 18 (HealthDay News) -- For patients with prostate cancer that has a low risk of progression, active surveillance, also known as "watchful waiting," may be a suitable treatment option, according to a large-scale study from Sweden.

The issue of how (or whether) to treat localized prostate cancer is controversial because, especially for older men, the tumor may not progress far enough to cause real trouble during their remaining expected lifespan. In those cases, deferring treatment until there are signs of disease progression may be the better option.

The researchers looked at almost 6,900 patients from the National Prostate Cancer Registry Sweden, age 70 or younger, who had localized prostate cancer and a low or intermediate risk that the cancer would progress. From 1997 through December 2002, over 2,000 patients were assigned to active surveillance, close to 3,400 underwent radical prostatectomy (removal of the prostate and some surrounding tissue), and more than 1,400 received radiation therapy.

After a median follow-up of just over 8 years, the surveillance group had a much higher death rate from causes other than prostate cancer -- 19.2 percent, compared with 6.8 percent in the prostatectomy group and 10.9 percent in the radiation therapy group.

This suggests that patients with a shorter life expectancy were more often selected for active surveillance rather than surgery or radiation therapy, the researchers said.

The patients who underwent surgery for prostate cancer had a lower risk of dying from prostate cancer than those in the active surveillance group. However, the difference in absolute risk of patients dying from prostate cancer was very small -- only 1.2 percent after 10 years of follow-up.

The researchers concluded that, based on these findings, active surveillance is the best strategy for many patients with low-risk prostate cancer.

"With a 10-year prostate cancer-specific mortality of less than three percent for patients with low-risk prostate cancer on surveillance, this strategy appears to be suitable for many of these men," wrote Dr. Par Stattin, of Umea University, and colleagues.

The study was published online June 18 in the Journal of the National Cancer Institute.

More information

The U.S. Agency for Healthcare Research and Quality has more about treatment of localized prostate cancer.



-- Robert Preidt



SOURCE: Journal of the National Cancer Institute, June 18, 2010, news release.


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Waiting to Clamp the Umbilical Cord May Be Better for Babies
2. Waiting Safe for Some at Risk of Glaucoma
3. Xyngular™ Distributors Continue Waiting For Xyngular Xyng™ As Zija's XM3™ "Happy Pill" Reaches Record Sales
4. Trustmark and HealthFitness Announce Early Termination of Hart-Scott-Rodino Waiting Period
5. Get Vaccinated Against a Second Wave of H1N1 Flu for Only $15 And no Waiting in Long Lines
6. Women Arent Waiting to Seek Infertility Help
7. Lymphoma Survivors Often Miss Out on Follow-Up
8. UNC study helps explain why black patients with lung cancer have surgery less often than whites
9. Most Doctors Giving Pap Test Too Often
10. Putting New Medical Guidelines Into Practice Often Difficult
11. Major Depression Often Follows Brain Injury
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
'Watchful Waiting' Often Best Strategy for Slow-Moving Prostate Cancer
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance Group, ... Dallas, Miami, and Raleigh regions, is organizing an extended charity drive to benefit ... deadly chromosome abnormality. , After struggling since birth with several health challenges, T.J. ...
(Date:10/13/2017)... IL (PRWEB) , ... October 13, 2017 , ... ... which established the certification process to promote standards of excellence for the field ... Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that ... insurance companies have a waiver for care if the client has a cognitive impairment ... family pays for care, is often waived, so the benefits from their insurance start ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed ...   ... Jim Bertolina, ... Tom Tefft ... medical device executive Josh Stopek , PhD, who has led R&D and business development ...
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
Breaking Medicine Technology: